Sight Sciences, Inc. (SGHT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$8.35-0.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Sight Sciences raised revenue guidance to $83-$89 million for 2026. The company focuses on managing operating expenses near $93-$96 million. It has a strong product portfolio for eye disease treatment. Litigation risks exist but are being managed.
The company is still loss-making and faces ongoing patent lawsuits. Earnings remain negative with no clear path to profit. Operating expenses are high and may pressure cash flow.
The price is about 24% below our fair value near $7. Analysts expect 13% revenue growth. We see risk from losses and litigation but some growth upside.
Breaks if: Unfavorable court ruling causing large damages or injunction
Breaks if: Operating expenses exceed $96 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. SGHT is currently loss-making but has shown signs of revenue growth and market expansion, making it a name to watch in the coming months.
The market seems to have priced in a justified valuation, with a low expectations gap. SGHT trades at a premium compared to its peers, indicating that some growth potential is already reflected in its valuation.
Management is focused on increasing revenue guidance and managing operating expenses, with recent results showing a positive trajectory in revenue growth. However, the company remains loss-making and operates in a high-risk environment, which could impact its fundamentals.
The future performance of SGHT may depend on its ability to raise guidance in upcoming quarters and the overall health of the job market. Additionally, the performance of larger healthcare companies could influence SGHT's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The company expects adjusted operating expenses for full year 2026 to range from $93 million to $96 million.
Breaks if: Revenue falls below $83 million in FY26
Raise full-year 2026 revenue guidance reflecting growth in Interventional Glaucoma and Interventional Dry Eye segments.
Stated as a priority in 3 of last 3 quarters. Revenue grew 20% year-over-year in 2026-Q2 to $23.4 million, and management raised full-year 2026 revenue guidance from $83-$89 million in 2026-Q1 to $88-$92 million in 2026-Q2. The trajectory is delivering with accelerating revenue growth and upward guidance revisions.
“Sight Sciences raised its revenue guidance for full year 2026 to range from $88 million to $92 million, representing year-over-year growth of 14% to 19%.”
“Sight Sciences raises its revenue guidance for full year 2026 to range from $83.0 million to $89.0 million, representing growth of 7% to 15%.”
“Sight Sciences expects its revenue for full year 2026 to range from $82 million to $88 million, representing growth of 6% to 14%.”
In the next 1 to 3 years, SGHT's growth potential hinges on effective management execution and external market conditions. Not investment advice.